CLINICAL_TRIALS
trial_result
· 2015-01-06
Clinical Trial Update: Safety And Efficacy of BIBF 1120 in Idiopathic Pulmonary Fibrosis [Phase 2]
Summary
Phase 2 trial results assess safety and efficacy of BIBF 1120 (nintedanib) in idiopathic pulmonary fibrosis, with sponsor Boehringer Ingelheim reporting the res…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Fibrosis | Phase 2 | Status: COMPLETED | Results posted: 2015-01-06